HomeBayer’s asundexian first FXIa inhibitor approved by US Food and Drug Administration...

Bayer’s asundexian first FXIa inhibitor approved by US Food and Drug Administration for secondary stroke risk reduction

The US Food and Drug Administration has granted marketing authorisation for Bayer’s asundexian, 50 mg tablets, under the brand name Sunharbo.

The product is indicated in combination with antiplatelet therapy to reduce the risk of stroke in adults with recent non-cardioembolic ischemic stroke (National Institutes of Health Stroke Scale ≤15) or high-risk transient ischemic attack (TIA).

Reducing the risk of another stroke after an initial event is often referred to as secondary stroke prevention. Sunharbo (asundexian) is the first approved FXIa inhibitor worldwide.

Stroke burden

Stroke affects approximately 12 million people worldwide each year, including 795,000 individuals in the U.S.

It remains the second leading cause of death and the third leading cause of death and disability combined worldwide and has been recognised as an urgent global public health challenge, including by the World Health Assembly, which adopted the first-ever resolution on stroke in May 2026.

In the US, between 1990 and 2021, the prevalence of ischemic stroke increased by approximately 66%, with stroke-related mortality rising by 16%.

Despite current guideline recommendations for stroke prevention, a significant proportion of survivors experience another stroke.

Approximately one in 10 non-cardioembolic ischemic stroke survivors will have another stroke within one year and one in five will have another stroke within five years.

Preventing stroke is a major priority for stroke survivors and often considered as valuable as preventing death.

- Advertisment -
- Advertisment -
- Advertisment -

Most Popular

Popular categories